BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
SAN DIEGO, Oct. 17, 2016 -- SENTÉ, a privately held specialty aesthetics company pioneering the development of differentiated medical grade skincare products based on the science of glycosaminoglycan’s, today announced that the company has received a new patent grant, Process For The Purification Of Heparan Sulfate And Use Thereof In Cosmetological And Dermatological Preparations (U.S. Patent No. 9,4330,099) by the United States Patent and Trademark Office (USPTO). The company’s patent estate has now produced patents in Europe and the United States, further strengthening its ability to distribute innovative skin care products worldwide.
“The issuance of this patent is a major milestone for the company and comes at a time when we are gaining significant traction,” said Laurent Combredet, Chief Executive Officer. “This further solidifies our IP position and adds to our vision of becoming a leading aesthetics company dedicated to pioneering glycosaminoglycan science.”
“Our focus is to remain dedicated to the development of products based on rigorous science and clinical research,” said Faheem Hasnain, Chairman of the Board of Directors. “This patent grant allows us to continue developing innovative and market disrupting technologies in the US and abroad.”
About SENTÉ:
SENTÉ is a privately held specialty aesthetics company leveraging its expertise and foundation in biotechnology to deliver novel, science-based skin care products. SENTÉ is a recognized leader in the development of innovative and targeted medical skincare products based on glycosaminoglycans. Founded in 2007 and based in San Diego, California, further information may be found at http://sentelabs.com/. SENTÉ products are available through its exclusive network of physicians and medically supervised spas.
Media Contact: Creative Media Marketing Danielle Hale [email protected] p: 212.979.8884 ext. 213
